Natural Compounds with Antioxidant in Maintaining Eye Health: Comparison
View Latest Version
Please note this is a comparison between Version 4 by Jessie Wu and Version 3 by Jessie Wu.

An antioxidant compound can be defined as a substance that can delay or prevent oxidation. The body uses different strategies against the production and accumulation of reactive oxygen species (ROS): firstly, antioxidant enzymes are used, as already reported, such as catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-px). It is important to remember that some antioxidant enzymes need micronutrients to function properly, such as zinc, selenium, copper and manganese. Secondly, ROS can be reduced or neutralized by the intake of antioxidant nutrients, such as vitamin E (a-tocopherol), beta-carotene, and vitamin C, among others. An insufficient intake of foods with antioxidant function or an unbalanced diet can alter the body’s natural antioxidant system and facilitate the damage induced by ROS. Additional defense mechanisms include antioxidant compounds, such as metallothionein, melanin, and glutathione. Eye health is crucial, and the onset of diseases can reduce vision and affect the quality of life of patients. Evidence has accumulated that polyphenols (mostly deriving from Citrus Bergamia) represent a reliable source of antioxidants able to counteract oxidative stress accompanying early stages of eye diseases. Luteolin in particular has been found to protect photoreceptors, thereby improving vision in many disease states. Moreover, a consistent anti-inflammatory response was found to occur when curcumin is used alone or in combination with other nutraceuticals. Additionally, Coenzyme Q10 has been demonstrated to produce a consistent effect in reducing ocular pressure, thereby leading to protection in patients undergoing glaucoma. Both grape seed extract, rich in anthocyanosides, and polynsatured fatty acids seem to contribute to the prevention of retinal disorders. A combination of nutraceuticals and antioxidants may represent the right solution for a multi-action activity in eye protection.

  • eyes diseases
  • Vitamin A
  • lutein

1. Vitamin A and Lutein

Among dietary factors, vitamin intake has become increasingly positive in reducing oxidative stress and, as a result, improving the outcome of many eye pathologies. Vitamin A is a fat-soluble life-essential group of compounds characterized by an unsaturated isoprenoid chain structure. Famously, vitamin A performs important functions including cell proliferation, reproduction, foetal growth and development, vision in darkness, corneal and conjunctiva development, immune system functioning, and central nervous system formation [1]. Unlike water-soluble vitamins, vitamin A easily accumulates in the body, especially in the liver and adipose tissue. This characteristic determines the advantage of resisting the development of clinical deficiency symptoms, but at the same time, it has the disadvantage of being able to provide accumulation toxicity. Vitamin A can be supplied in the diet both from products of animal origin, such as retinol, and vegetable carotenoids, such as provitamin A [2]. As already discussed, the retina is responsible for visual perception, mediated through specific structures known as cones and rods that are fundamental for vision in light and dark conditions, respectively. Active vitamin A is associated with a protein receptor coupled to protein G, the complex known as rhodopsin, generating a chain of reactions whose last consequence is the transmission of optical perceptions to the brain via the optic nerve [1]. Vitamin A is responsible for the maintenance of homeostasis reduction–oxidation. In fact, retinol binds to different proteins, acting as a redox reagent. In addition, carotenoids, such as β-carotene, α-carotene, lutein, lycopene, and cryptoxanthin, are well-known antioxidants [3][4]. An excessive intake of vitamin A is potentially toxic; toxicity has been associated with 100,000 RE per day (1 RE = 1 μg retinol) in adults and 10,000 RE per day in children. In women in the first trimester of pregnancy, a dose of 3000–9000 RE per day created teratogenic effects. The Group of Experts on Vitamins and Minerals have not been able to set a safe limit for Vitamin A; therefore, it is recommended that a maximum intake per day is 700 lg for men and 600 lg for women [5]. Among the approximately 850 types of naturally occurring carotenoids, very few of them are present in human tissues. Among these it is important to mention lutein and its stereoisomers, zeaxanthin and meso-zeaxanthin, present in the human retina [6]. It is a class of a carotenoid, named xanthophyll, that cannot be synthesized de novo in the human body, and are absorbed only through diet. The most xanthophyll-rich foods, including lutein and zeaxanthin, are leafy green vegetables, such as cabbage, broccoli, peas, spinach, lettuce, and also egg yolk [7]. These compounds are hydrophobic; however, due to the presence of the hydroxyl group, lutein and zeaxanthin are relatively polar compounds. After their intake, food carotenoids are dispersed in gastric juice and incorporated into lipid droplets, transferred to micelles with food lipids, and finally into the bloodstream. Therefore, fat-rich diets generally facilitate the absorption of dietary carotenoids [8]. Lutein is particularly concentrated in the central portion of the retina, where the photoreceptor cells, responsible for visual acuity and central vision, are located. In the macula of the retina are found: zeaxanthin, in the middle-peripheral region; meso-zeaxanthin, in the epicentre; and lutein, concentrated in the periphery. The absence of these three cartenoids is often used to predict the risk of developing macular diseases [8]. Lutein is also found in the lens, protecting it from age-related eye diseases, such as cataracts [9]. Lutein is retained in the human retina for a prolonged period of time and it has been shown that, even after three months from the interruption of lutein supplementation, the optical density of the macular pigment remains high despite its low serum concentration [10][11]. Lutein has been shown to exert an extremely powerful antioxidant action with several mechanisms of action: (1) render the role of the oxygen singlet poorly active; (2) reduce or eliminate free radicals; (3) filter blue light, thereby reducing phototoxic damage to photoreceptor cells; (4) reduce the expression of inducible nitric oxide synthase (iNOS) [12][13][14]. In addition, lutein is able to turn off the inflammatory process, inhibiting the pro-inflammatory cytokine cascade, the expression of nuclear-kB transcription factor (NF-kB), and the activation of the complement system [15][16][17][18]. Many clinical studies have attributed lutein to antioxidant and anti-inflammatory properties in the eye, justifying a benefit in some diseases such as age-related macular degeneration, diabetic retinopathy, cataracts, retinitis pigmentosa, and myopia [19][20]. Lutein supplementation showed a relatively high safety profile and was classified as “GRAS” by the US Food and Drug Administration (FDA) [21]. Although German, Canadian and American studies have reported daily intakes of lutein of 1.9, 1.4, and 2 mg, respectively [22][23], these results have been shown to be undervalued, and the randomized clinical trial “Age-Related Eye Disease Study 2” (AREDS 2) showed a lutein intake of 10 mg per day over 5 years in more than 4000 patients. Subsequently, the Council for Responsible Nutrition (CRN) stated that lutein intake is safe up to 20 mg/day [24].

2. Vitamin C and Coenzyme Q10

Vitamin C (ascorbic acid) is, chemically, a low-molecular-weight carbohydrate capable of donating electrons to free radicals from both the second and third carbon, quenching their reactivity and acting as a reducing agent. While most vertebrates can synthesize this compound, humans, together with guinea pigs, some fish, birds, and insects, rely exclusively on dietary intake to maintain the body’s levels of vitamin C. This is a hydrophilic vitamin, and despite its small size, it does not cross the plasma membrane by passive diffusion [25]. During the detoxification reactions of ROS, vitamin C oxidizes to dehydroascorbate, but this oxidized form can subsequently be reduced to generate vitamin C again by glutathione-dependent enzymes. However, if the oxidative damage is continuous, dehydroascorbate undergoes an irreversible degradation; in the event in which vitamin C is present in excessive doses, it can act as a pro-oxidant, contributing to the formation of hydroxyl radicals and increasing oxidative damage. This means that vitamin C can pass from being an antioxidant in physiological conditions to a pro-oxidant under pathological conditions [26]. Vitamin C is particularly present in the eye in the aqueous humor (saline fluid that is located between the cornea and the crystalline) and vitreous humor (connective tissue of gelatinous consistency occupying the eyeball cavity between the posterior surface of the lens and the retina). Particularly in these districts, its concentration exceeds plasma concentrations by 20 to 70 times [27]. In the eye, vitamin C absorbs UV light, preventing the penetration of UV rays and subsequent photoinduced oxidative damage in the tissues, behaving as a physiological “sunscreen” [28]. In addition, vitamin C can scavenge or quench the superoxide anion radical, hydrogen peroxide, hydroxyl radical, singlet oxygen, and reactive nitrogen oxide [29], protecting the cornea, the lens and other ocular tissues against oxidative damage. Finally, vitamin C has been shown to play a role in the prevention of lipid peroxidation of membranes [30]. Since it has been shown that individuals with vitamin C deficiency developed cataracts more easily than others, and that there was a close correlation between vitamin C and the health of the crystalline, numerous studies have been conducted on the relationship between vitamin C and the risk of cataracts [31][32]. The recommended daily allowance (RDA) based on the intake of vitamin C, is 75 and 90 mg/day for women and men, respectively, established by the U.S. Institute of Medicine (IOM) in 2000 [33]. Recent data suggest that the current RDA for vitamin C set by the IOM for men and women may be too low. On the basis of a comprehensive review of the scientific evidence, it was concluded that 200 mg/d is the optimum intake of vitamin C for the majority of the adult population, to the advantage of the health benefits for the eye [34]. Coenzyme Q10 (coQ10) possesses a quinone structure and, for this reason, is also known as ubiquinone. The chemical structure of coQ10 is very similar to that of vitamin K; nevertheless, this cofactor is not considered a vitamin because it is the only fat-soluble antioxidant that animal cells synthesize de novo in the body [35]. It is found in all cell membranes and its main function is to be a cofactor of the mitochondrial enzymes that cooperate in the formation of ATP, an energy source needed to perform cellular biochemical functions. In particular, this liposoluble compound works to transport the electrons in mitochondria during aerobic cellular respiration, from complex I (NAHD ubiquinone oxioreductase) and complex II (succinate ubiquinone reductase) to complex III (ubiquinone cytochrome c reductase). Another function of coQ10 is to participate in the creation of a proton gradient in the intermembrane space [36]. This compound also possesses direct and indirect antioxidant properties in its reduced form (CoQ10H2). The direct antioxidant property is achieved by reducing the accumulation of ROS, while the indirect action occurs with the regeneration of a form of vitamin E (α-tocopherol) [37]. CoQ10 collaborate in lowering the lysosomal pH, transporting H+ ions inside, in order to facilitate an acidic environment necessary to degrade cellular debris [38]. Finally, it has been recognized that coQ10 participates in gene expression, and this could explain its effects on overall tissue metabolism [39][40]. Since the quantity of coQ10 present in the body is determined by two sources, biosynthesis [41][42] and dietary supplementation, its deficiency may occur for the following reasons: (1) reduced dietary intake; (2) impaired biosynthesis; (3) increased usage by the body [43]. A shortage of coQ10 is mainly manifested by reduced energy metabolism, impaired protection from free radicals, and deacidification of lysosomes [44][45][46]. Since the retina is the most metabolically active tissue of the body, with the highest consumption of energy (tissue/size ratio), patients with coQ10 deficiency may develop retinopathies, suggesting that coQ10 can play an important role in pathogenesis of retinal conditions [47][48]. In addition, a study by Que et al. showed higher coQ10 concentrations in young people (30 years) compared to older human retinas (80 years), highlighting how the oxidative stress plays a key role in the pathogenesis of many age-related diseases, such as atherosclerosis, cataracts, and Alzheimer’s disease [49][50][51]. In this way, the accumulation of ROS in aging results in increased cell damage that mediates the apoptotic mechanisms of cell death [52]. Age-related macular degeneration (AMD) causes loss of central vision, which has a significant impact on quality of life. Plasma coQ10 levels are substantially reduced in patients with AMD, compared with control patients, and this suggests an association between coQ10 and AMD pathogenesis [53]. Since the retina and the ocular macula are exposed to light more than any other organ or tissue in the body, these districts will be particularly sensitive to oxidative stress and lipid peroxidation. The result of this oxidative damage leads to apoptotic cell death [54]. Glaucoma is characterized by the loss of RGC, which are fundamental in the transmission of the signal from the photoreceptors to the optic nerve. As the prevalence of glaucoma increases with age, there may be a possible correlation between RGC and coQ10 deficiency in old age [55][56]. Experimental studies have shown that intravitreal administration of coQ10 minimizes apoptosis in RGC. This supported the neuroprotective role of coQ10 [57][58]. The normal concentration range of coQ10 in human plasma is 0.8–1.2 mg/L, and in cases of deficiency, supplementation typically given to adults at 1.2–3 g/day [59].

3. Astaxanthin

Carotenoids are a class of compounds with over 600 natural fat-soluble pigments that play a crucial role in the photosynthetic process, as well as protective activity against damage caused by excessive exposure of light and oxygen. They are taken through the diet, constituting a robust nutritional role as a source of vitamin A [60]. Their oxygenated derivatives are known as xanthophylls; both classes of pigments share a structural scheme consisting of alternating single and double bonds, responsible for the absorption of the excess energy contained in other molecules and carrying out, accordingly, an antioxidant role [61]. Astaxanthin, a xanthophyll carotenoid, is a naturally occurring red pigment in numerous living organisms (bacteria, microalgae and yeasts), present as a secondary metabolite. This compound is biosynthesized by phytoplankton and microalgae (such as Haematococcus pluvialis, Chlorella zofingiensis and Xanthophyllomyces dendrorhous), which are the basis for the feeding of zooplankton and krill, the ideal food of animal species which store this pigment in the skin and adipose tissue. Finally, all the superior aquatic species that feed on these foods become rings of the trophic chain containing astaxanthin. This carotenoid is responsible for the colouring of some sea creatures, including salmonids, tuna, shrimps, crustaceans, lobsters, and crayfish [62]. The chemical structure of astaxanthin provides a long chain structure and two terminal polar groups; this particular conformation provides the compound with both lipophilic and hydrophilic properties. Precisely because of this feature, astaxanthin extends through the entire double-layer membrane, carrying out its protective activity both inside and outside the cell membrane [63][64]. Astaxanthin has been shown to have numerous beneficial activities on human health, including a protective effect on the skin, the cardiovascular and nervous system, and antioxidant, anti-inflammatory, anti-cancer, and antidiabetic properties, among others [65][66]. In the last two decades, the potential role of astaxanthin in protecting eye health has been highlighted, showing a significant improvement in macular degeneration, cataracts, diabetic retinopathy, and glaucoma [67]. To date, astaxanthin is considered to be the most beneficial antioxidant carotenoid provided in nature; in fact, it is more potent than most known antioxidants, according to the following ratios: 6000 times more powerful than vitamin C; 550 times stronger than vitamin E (alpha-tocopherol); and 40 times more powerful than beta-carotene [68]. The reason for this exceptional oxidative protection is explained by its chemical structure: the terminal polar groups quench free radicals and the double bonds, its intermediate segment, removes high-energy electrons [69]. The peculiarity of astaxanthin is to be able to neutralize single oxygens and radicals in both the non-polar (hydrophobic) and polar (hydrophilic) zones [70]. Several studies have confirmed the antioxidant efficacy of astaxanthin and have identified the reduction of oxidative marker levels, such as malondialdehyde (MDA), and the increase in antioxidant agents including SOD, CAT and GPX1 [71][72][73]. Therefore, wresearchers can conclude that astaxanthin exerts antioxidant activities not only through direct scavenging of radicals, but also by activating the cellular antioxidant defense system [74][75]. Finally, astaxanthin exerts a robust anti-inflammatory [76][77] and anti-apoptotic activity [78][79]. In the last two decades, it has been shown that treatment with astaxanthin improves many eye conditions. For example, Otzuka et al., showed that treatment with axanthin 100 mg/kg could inhibit retinal dysfunction caused by light [80].
Trehalose, also referred to as α,α-Trehalose or α-D-Glucopyranosyl-α-D-glucopyranooside, is a non-reducing disaccharide consisting of two portions of glucose linked through an α,α1,1-glucosidic bond [81]. This component is usually found in the environment in different species of plants, fungi, algae, bacteria, yeasts, insects, and other lower invertebrates, but never in mammals or other vertebrates. Once ingested with food, trehalose is hydrolyzed in the small intestine in two molecules of D-glucose through the trehalase enzyme. It is also known to be used as a sweetener; in industry as, a stabiliser or packaging material; in the pharmaceutical industry, as an excipient; and in the textile industry, as a texturing agent 2 [82]. The chemical structure of trehalose justifies the impossibility of crossing cell membranes; to date, it has been established that this compound can penetrate the cytosol through vesicular internalization of endocytosis [83][84]. Trehalose has also recently been used for its therapeutic effects in the treatment of cardiometabolic disease and degeneration in animal and human models [85]. Takahashi et al. [86] found that trehalose reduced neuronal damage in a model of ischemia in rabbits. In the case of neurodegeneration or traumatic brain injury, oral administration of 2% trehalose has been shown to improve the cognitive characteristics involved in injured brain areas [87]. In addition, this compound induced the increase of zinc and iron in the brain, essential for the maintenance of brain functions [88][89]. Finally, trehalose increased the expression of proteins involved in synaptic activity, neuroprotection, and neurogenesis [90]. Trehalose has become known for its pro-autophagic action; it is able to eliminate and recycle damaged macromolecules in response to cellular stress. For this reason, it was considered protective against the aggregation of the β-amyloid protein in neuronal cell lines [91] and metabolic disorders. More generally, it is possible to affirm that the action of this compound guarantees homeostatic paths that depend on the type of tissue involved [92]. Trehalose has been found to be a stress-reactive factor; in particular, it is a response factor when the cells of the organisms that produce it are exposed to environmental stress, such as heat, cold, dessication, and oxidation. When stress conditions become excessive, these organisms synthesize trehalose, which helps them maintain cellular integrity. With this strategy, these organisms can prevent the denaturation of proteins, facilitate their stabilization, and inhibit protein aggregation [93][94]. Another important function of trehalose is to properly moisturize the dried tissues of the organisms that synthesize this compound. This strategy, known as the “water hypothesis”, is based on the ability of trehalose to form hydrogen bonds between its polar groups and lipids or membrane proteins [95]. In this way, trehalose can maintain the integrity of phospholipids guaranteeing the functional properties of biological membranes [96]. There is a large volume of evidence that testifies to a specific role of trehalose in performing antioxidant and anti-inflammatory effects and, in recent years, has shown beneficial effects in ophthalmology [97]. For example, cell exposure to H2O2 causes severe oxidative damage to the amino acids of cellular proteins; nevertheless, trehalose is able to reduce such damage, in this way protecting both proteins and lipids of the membrane [98]. Trehalose has an established ability to maintain the degree of hydration; this compound has been used to protect the cells of the anterior ocular surface in dry-eye disease [99]. In addition, the effect of trehalose was enhanced when it was added to a single formulation with hyaluronate, an anionic glycosaminoglycan polysaccharide with lubricative and water-retaining properties [100]. The trehalose highlighted the ability to reduce photodamage caused by UVB radiation in the epithelium of the cornea [101]. Following UVB irradiation, trehalose was found to reduce the resulting corneal disorders, speeding up healing, suppressing neovascularization, restoring corneal transparency, and restoring proper immunohistochemistry [102]. Chen and Haddad (2004) also highlighted the effectiveness of trehalose against hypoxic or anoxic lesions. The cornea is not only affected by damage caused by ROS, but also by insufficient oxygen supply. In these cases, apoptotic death occurs; trehalose has been shown to effectively suppress these disorders [103].

5. Curcumin and Quercetin

Curcumin is a pigment insoluble in water extracted from the rhizome of Curcuma longa, a species that belongs to the Zingiberaceae family. The obtained powder contains 2–5% curcumin. Curcumin is a biologically active phytochemical compound with health benefits, and its extract also contains β-carotene, lycopene, epigallocatechin gallate, and quercetin [104][105]. In recent years, several studies have confirmed the use of curcumin for the prevention and treatment of many diseases, especially inflammatory diseases and cancer [106][107]. Curcumin inhibits the production of free radicals, and therefore shows antioxidant properties [108]. The effect of curcumin on oxidative damage is based on its ability to scavenge ROS and reactive nitrogen species (RNS) [109]. It can modulate the activity of active enzymes in the neutralization of free radicals, GSH-Px, CAT, and SOD [110]. In addition, it can inhibit enzymes that generate ROS, such as lipoxygenase/cyclooxygenase and xanthine hydrogenase/oxidase Finally, being lipophilic, curcumin is able to eliminate peroxylic radicals, behaving like vitmin E. Antioxidant properties of curcumin cause the inhibition of oxidative stress and this reduces the risk for many lifestyle diseases [111]. In addition, curcumin exerts an anti-inflammatory effect; it lowers the expression of the gene IκBα, gene cyclooxygenase-2 (COX-2), prostaglandin E-2 (PGE-2), interleukin 1-6-8 (IL-1, IL-6, IL-8), and tumor necrosis factor α (TNF-α). The anti-inflammatory effect is also exerted by the ability of curcumin to activate the proliferator-activated peroxisome receptor γ (PPAR-γ), a nuclear receptor protein that binds to the peroxisome proliferator response element (PPRE) and regulates gene transcription [112]. Recently it has been highlighted that ROS are fundamental regulators of angiogenesis, the process that allows new blood vessels form within the vascular system, and that vascular function critically depends on the amount of ROS present. In fact, while high doses of ROS induce oxidative stress and subsequent cell death, both conditions inhibit angiogenesis; low doses of ROS promote it through some sublethal damage to the cell membrane, subsequently releasing the growth factor of fibroblasts FGF-2, which are directly involved in angiogenesis [113][114]. Given the properties of curcumin, this compound could be used in the treatment of diseases related to angiogenesis, including eye diseases [115][116]. Most retinal diseases, as already mentioned, imply an abundance of ROS and reduced levels of scavenger antioxidants. In particular, RGC and photoreceptors are extremely sensitive to oxidative stress damage, and it is known that the accumulation of ROS is often involved in several diseases of the retina, such as uveitis, age-related macular degeneration, diabetic retinopathy, retinal tumors, and proliferative vitreoretinopathy (PVR) [117]. In order to know the effect of curcumin after an oxidative stress insult, Munia et al., have shown that this nutraceutical compound was capable of protecting human retinal epithelial cells from death [118]. Dry-eye disease is characterized not only by reduced secretion of tears, but also rapid tear evaporation, responsible for the damage to the eye surface [119]. This disease includes an inflammatory process involving IL-6, IL-8, IL-1β [120]. It has been shown that curcumin could exert a protective effect through its anti-inflammatory activity, inhibiting the expression of pro-inflammatory cytokines in conjunctiva [121]. Uveitis is an inflammation of the eye that includes the iris and adjacent tissue. Lal et al. reported an improvement in patients with chronic uveitis who have been given oral capsules of curcumin (75 mg/capsule) [122]. A decrease in aqueous flare and keratic precipitates was observed after treatment. Its beneficial effects can be derived from their antioxidant, anti-inflammatory, and antifibrinolytic properties [119]. Because curcumin has low oral solubility and bioavailability, its biomedical potential cannot be exploited in animals and humans [123]. The exogenous curcumin administered in humans for a period of about 8 weeks has been shown to be able to adequately perform all the functions of this natural compound [124]. Quercetin is a member of the subclass of flavonols and is abundant in the human diet. It has received considerable attention from the scientific community in recent years thanks to numerous effects on human health, including antioxidant [125], anti-inflammatory [126], anti-cancer [127][128], anti-aging [129], and anti-autoimmune effects, [130] and effects upon metabolic pathologies [131]. The eye surface serves as a protective and functional barrier for the rest of the eye. Diseases of the eye surface can affect the structure of the cornea or conjunctiva, leading to corneal thinning, inflammation, and visual deficits [132]. Prolonged inflammation in these districts can lead to a partial or even complete loss of vision, affecting quality of life. Unfortunately, to date, wresearchers do not possess a non-invasive treatment that can preserve corneal function; surgery and corneal transplantation remain the only solution [133]. Given the problems and side effects involved in a corneal transplant, scientists have sought an alternative. The effectiveness of the administration of ocular drugs depends on many factors, including drug absorption, bioavailability, and retention on the front surface. Lipophilic drugs, in general, are associated with increased corneal epithelial permeability, and the solubilization of these compounds in water eye drops was tested. Topical application of quercetin or other flavonoids may be more effective in treating conditions affecting the eye surface [134]. Studies have shown that a protective role is carried out by quercetin when administered at an average daily consumption of about 16–23 mg/day in human populations [135][136][137]. In Figure 1, the chemical structures of the examined compounds are represented.
Life 13 00077 g003 550
Figure 1. Chemical structures of the examined compounds.

6. PUFAs

Polyunsaturated fatty acids (PUFAs) are lipids whose hydrocarbon chain has a polar hydrophilic end with a carboxyl group (-COOH) and another end with a non-polar hydrophobic methyl group (-CH3). The n-3 and the n-6 represent two classes of PUFAs defined as “essential”, as they must be taken with the diet because humans do not have the desaturases Δ12 and Δ15, enzymes that catalyze the formation of double bonds along the hydrocarbon chain [138]. Specifically, linoleic acid (LA, 18:2) is the n-6 PUFA from which γ-linolenic and arachidonic acid derive, while from α-linolenic acid (ALA, 18:3), one derives n-3 PUFAs, such as eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3). LA is present in safflower, soy, and corn oils, while the vegetables that contain ALA are flaxseed, beans, nuts, and the leaves of some green plants. In the liver, the amount of EPA and DHA obtained from the metabolism of ALA is very small, therefore they must be taken with the diet. Both lean and fatty marine fish, fish oil, and algal-derived supplements are particularly rich in EPA and DHA, although they are present in small quantities in many foods of animal origin. For this reason, they must be present in the daily diet [139]. In particular, EPA and DHA can be present in cellular phospholipid membranes and have powerful antioxidant and anti-inflammatory effects [140]. The positive effects of taking n-3 PUFAs are well documented; in fact, the long-term effects against certain pathologies, such as cardiovascular diseases, neurodegenerative diseases, and osteoarthritis, are known [141]. The n-3 PUFAs are also implicated in diseases affecting the eye. For example, in the case of neovascular eye diseases, such as retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration, current therapies have significant side effects. Clinical and experimental investigations have shown that such treatments could be accompanied by a higher intake of n-3 PUFAs [142]. Despite conflicting results between fundamental and clinical research, it appears that PUFAs can act positively on the damage that determines the pathogenesis of glaucoma [143]. Indeed, the effect of PUFAs can be both on intraocular pressure (IOP) and on survival of RGCs. In the first case, endogenous prostaglandins (PGs), obtained from the metabolism of PUFAs, by activating the EP4 and FP receptors, reduce IOP. In the second case, thanks to their anti-inflammatory and antioxidant effects, n-3 PUFAs can reduce the inflammation and oxidative stress responsible for the RGC dysfunction or death [144]. In particular, patients with pseudoexfoliative (PEX) glaucoma have benefited from the administration of a high, rich DHA nutraceutical formulation that reduced oxidative stress and inflammation. The fact that PUFAs may have beneficial effects for glaucoma is linked to their positive action on endothelial dysfunction and atherosclerosis [145]. Regarding cataracts, a study was conducted on male Wistar rats, in which it was found that the antioxidant and anti-inflammatory activity of lutein increased in the presence of EPA + DHA [146]. In particular, micellar lutein with EPA + DHA has been shown to positively regulate α-crystalline chaperone function [147]. Chang et al. demonstrated a reduction in free fatty acid levels in patients with senile cataracts compared with normal controls. The levels of DHA were particularly low [148]. Studies on the molecular mechanisms responsible for aging in the eye have allowed uresearchers to define the involvement of the ELOVL2 (elongation of very-long-chain fatty acids-like 2) enzyme in the regulation of molecular aging in the retina [149]. The ELOVL2 enzyme catalyzes an elongation reaction of n-3 and n-6 PUFAs, which are essential for retinal function. DHA is the main PUFA in the retina and is involved in the photoreceptor function in retinal development and has an antioxidant role [150]. The involvement of PUFAs in AMD, which is the leading cause of blindness in the elderly, has been demonstrated. In particular, the analysis of the eyes of subjects with AMD showed a reduction in PUFAs, and a direct correlation was also reported between the reduced dietary intake of n-3 PUFAs and the increased risk of AMD. Given the function of the ELOVL2 enzyme, it appears that this is directly involved in the onset of AMD along with PUFAs [151]. 

7. Grape Seed Extract and Bergamot Polyphenolic Fraction

Grape seed extract has shown beneficial effects in many diseases, thanks to its composition as a flavonoid polyphenolic compound; its main components are: +catechin, −epicatechin gallate, gallate and −epigallocatechin [152]. Beneficial properties of grape seed include prevention and treatment of diabetes and its complications [153], prevention of obesity and inflammatory reaction [154][155], the ability to modify early cerebrovascular injury caused by hypertension [156], alleviation of exercise fatigue [157], protection of the myocardium from injury [158], lowering blood lipids, regulating the metabolism, and improving the intestinal flora [159][160]. Most of these activities are carried out thanks to the antioxidant effect of grape seed extract, which makes it more powerful and effective than other plant polyphenolic compounds [161][162]. Among the active ingredients present in grape seed extract, proanthocyanidins are responsible for the biological, therapeutic and pharmacological properties [163]. Many studies have looked at the correlation between grape seed and eye disease: for example, Mani Satyam et al. showed in an in vivo study in rats that the administration of grape seed extract one day before treatment with sodium selenite, capable of inducing cataract formation in animals, was able to significantly reduce the disease and its damage [164]. Another recent study showed that treatment with grape seed extracts was able to reduce the damage of retinal degeneration caused by aging, by attenuating the expression of some pro-inflammatory cytokines [interleukin 6 (IL-6), IL-12 and IL-1β)] or the formation of their messenger RNAs [165]. The protective effects of grape seed proanthocyanidins on retinal ganglion cells have also been confirmed by an important study by Li et al., demonstrating this result in several neurodegenerative disorders [166].

References

  1. Carazo, A.; Macáková, K.; Matoušová, K.; Krčmová, L.K.; Protti, M.; Mladěnka, P. Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity. Nutrients 2021, 13, 1703.
  2. Saari, J.C. Vitamin A and Vision. Subcell Biochem. 2016, 81, 231–259.
  3. Koekkoek, W.A.; van Zanten, A.R. Antioxidant Vitamins and Trace Elements in Critical Illness. Nutr. Clin. Pract. 2016, 31, 457–474.
  4. Blaner, W.S.; Shmarakov, I.O.; Traber, M.G. Vitamin A and Vitamin E: Will the Real Antioxidant Please Stand Up? Annu. Rev. Nutr. 2021, 41, 105–131.
  5. Bartlett, H.; Eperjesi, F. An ideal ocular nutritional supplement? Ophthal. Physiol. Opt. 2004, 24, 339–349.
  6. Martini, D.; Negrini, L.; Marino, M.; Riso, P.; Del Bo, C.; Porrini, M. What Is the Current Direction of the Research on Carotenoids and Human Health? An Overview of Registered Clinical Trials. Nutrients 2022, 14, 1191.
  7. Perry, A.; Rasmussen, H.; Johnson, E. Xanthophyll (lutein, zeaxanthin) content in fruits, vegetables and corn and egg products. J. Food Compos. Anal. 2009, 22, 9–15.
  8. Bernstein, P.S.; Li, B.; Vachali, P.P.; Gorusupudi, A.; Shyam, R.; Henriksen, B.S.; Nolan, J.M. Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Prog. Retin. Eye Res. 2016, 50, 34–66.
  9. Li, B.; George, E.W.; Rognon, G.T.; Gorusupudi, A.; Ranganathan, A.; Chang, F.Y.; Shi, L.; Frederick, J.M.; Bernstein, P.S. Imaging lutein and zeaxanthin in the human retina with confocal resonance Raman microscopy. Proc. Natl. Acad. Sci. USA 2020, 117, 12352–12358.
  10. Manayi, A.; Abdollahi, M.; Raman, T.; Nabavi, S.F.; Habtemariam, S.; Daglia, M.; Nabavi, S.M. Lutein and cataract: From bench to bedside. Crit. Rev. Biotechnol. 2016, 36, 829–839.
  11. Yoshizako, H.; Hara, K.; Takai, Y.; Kaidzu, S.; Obana, A.; Ohira, A. Comparison of macular pigment and serum lutein concentration changes between free lutein and lutein esters supplements in Japanese subjects. Acta Ophthalmol. 2016, 94, e411–e416.
  12. Kijlstra, A.; Tian, Y.; Kelly, E.R.; Berendschot, T.T. Lutein: More than just a filter for blue light. Prog. Retin. Eye Res. 2012, 31, 303–315.
  13. Junghans, A.; Sies, H.; Stahl, W. Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Arch. Biochem. Biophys. 2001, 391, 160–164.
  14. Rafi, M.M.; Shafaie, Y. Dietary lutein modulates inducible nitric oxide synthase (iNOS) gene and protein expression in mouse macrophage cells (RAW 264.7). Mol. Nutr. Food Res. 2007, 51, 333–340.
  15. Chung, R.W.S.; Leanderson, P.; Lundberg, A.K.; Jonasson, L. Lutein exerts anti-inflammatory effects in patients with coronary artery disease. Atherosclerosis 2017, 262, 87–93.
  16. Liu, T.; Liu, W.H.; Zhao, J.S.; Meng, F.Z.; Wang, H. Lutein protects against β-amyloid peptide-induced oxidative stress in cerebrovascular endothelial cells through modulation of Nrf-2 and NFkB. Cell. Biol. Toxicol. 2017, 33, 57–67.
  17. Chang, J.; Zhang, Y.; Li, Y.; Lu, K.; Shen, Y.; Guo, Y.; Qi, Q.; Wang, M.; Zhang, S. NrF2/ARE and NF-kB pathway regulation may be the mechanism for lutein inhibition of human breast cancer cell. Future Oncol. 2018, 14, 719–726.
  18. Tian, Y.; Kijlstra, A.; van der Veen, R.L.; Makridaki, M.; Murray, I.J.; Berendschot, T.T. Lutein supplementation leads to decreased soluble complement membrane attack complex sC5b-9 plasma levels. Acta Ophthalmol. 2015, 93, 141–145.
  19. Li, L.H.; Lee, J.C.-Y.; Leung, H.H.; Lam, W.C.; Fu, Z.; Lo, A.C.Y. Lutein Supplementation for Eye Diseases. Nutrients 2020, 12, 1721.
  20. Buscemi, S.; Corleo, D.; Di Pace, F.; Petroni, M.L.; Satriano, A.; Marchesini, G. The Effect of Lutein on Eye and Extra-Eye Health. Nutrients 2018, 10, 1321.
  21. Ranard, K.M.; Jeon, S.; Mohn, E.S.; Griffiths, J.C.; Johnson, E.J.; Erdman, J.W., Jr. Dietary guidance for lutein: Consideration for intake recommendations is scientifically supported. Eur. J. Nutr. 2017, 56 (Suppl. 3), 37–42.
  22. Stahl, W. Macular carotenoids: Lutein and zeaxanthin. Dev. Ophthalmol. 2005, 38, 70–88.
  23. Food and Nutrition Board Staff, Panel on Dietary Antioxidants; Institute of Medicine Staff. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids; National Academy of Sciences: Washington, DC, USA, 2000.
  24. Shao, A.; Hathcock, J.N. Risk assessment for the carotenoids lutein and lycopene. Regul. Toxicol. Pharm. 2006, 45, 289–298.
  25. Pehlivan, F.E. Vitamin C-an antioxidant agent. In Vitamin C; Hamza, A.H., Ed.; IntechOpen: London, UK, 2017.
  26. Koppenol, W.H.; Hider, R.H. Iron and Redox Cycling. Do’s and Don’ts. Free Radic. Biol. Med. 2019, 133, 3–10.
  27. Shui, Y.B.; Holekamp, N.M.; Kramer, B.C.; Crowley, J.R.; Wilkins, M.A.; Chu, F.; Malone, P.E.; Mangers, S.J.; Hou, J.H.; Siegfried, C.J.; et al. The gel state of the vitreous and ascorbate-dependent oxygen consumption: Relationship to the etiology of nuclear cataracts. Arch. Ophthalmol. 2009, 127, 475–482.
  28. Barros, A.I.R.N.A.; Nunes, F.M.; Gonçalves, B.; Bennett, R.N.; Silva, A.P. Effect of cooking on total vitamin C contents and antioxidant activity of sweet chestnuts. Food Chem. 2011, 128, 165–172.
  29. Brubaker, R.F.; Bourne, W.M.; Bachman, L.A.; McLaren, J.W. Ascorbic acid content of human corneal epithelium. Investig. Opthalmol. Vis. Sci. 2000, 41, 1681–1683.
  30. Talluri, R.S.; Katragadda, S.; Pal, D.; Mitra, A.K. Mechanism of Lascorbic acid uptake by rabbit corneal epithelial cells: Evidence for the involvement of sodium-dependent vitamin C transporter 2. Curr. Eye Res. 2006, 31, 481–489.
  31. Liu, F.; Xiong, J.; Hu, J.; Ran, Z.; Wang, J.; Li, Z.; Chen, M.; Wang, Y. Vitamin C and risk of age-related cataracts: A systematic review and meta-analysis. Int. J. Clin. Exp. Med. 2018, 11, 8929–8940.
  32. Wei, L.; Liang, G.; Cai, C.; Lv, J. Association of vitamin C with the risk of age-related cataract: A meta-analysis. Acta Ophthalmol. 2016, 94, e170–e176.
  33. Institute of Medicine. Dietary Reference Intakes: The Essential Guide to Nutrient Requirements; National Academy of Sciences Press: Washington, DC, USA, 2006.
  34. Frei, B.; Birlouez, I.; Lykkesfeldt, J. What is the optimum intake of vitamin C in humans? Crit. Rev. Food Sci. Nutr. 2012, 52, 815–829.
  35. Bhagavan, H.N.; Chopra, R.K. Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic. Res. 2006, 40, 445–453.
  36. Acosta, M.J.; Fonseca, L.V.; Desbats, M.A.; Cerqua, C.; Zordan, R.; Trevisson, E.; Salviati, L. Coenzyme Q biosynthesis in health and disease. Biochim. Biophy. Acta (BBA)-Bioenerg. 2016, 1857, 1079–1085.
  37. Manzar, H.; Abdulhussein, D.; Yap, T.E.; Cordeiro, M.F. Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain. Int. J. Mol. Sci. 2020, 21, 9299.
  38. Hargreaves, I.; Heaton, R.A.; Mantle, D. Disorders of Human Coenzyme Q10 Metabolism: An Overview. Int. J. Mol. Sci. 2020, 21, 6695.
  39. Groneberg, D.A.; Kindermann, B.; Althammer, M.; Klapper, M.; Vormann, J.; Littarru, J.; Doring, F. Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. Int. J. Biochem. Cell Biol. 2005, 37, 1208–1218.
  40. Tsui, H.S.; Pham, N.V.B.; Amer, B.R.; Bradley, M.C.; Gosschalk, J.E.; Gallagher-Jones, M.; Ibarra, H.; Clubb, R.T.; Blaby-Haas, C.E.; Clarke, C.F. Human COQ10A and COQ10B are distinct lipid-binding START domain proteins required for coenzyme Q function. J. Lipid Res. 2019, 60, 1293–1310.
  41. Arenas-Jal, M.; Suñé-Negre, J.M.; García-Montoya, E. Coenzyme Q10 supplementation: Efficacy, safety, and formulation challenges. Compr. Rev. Food Sci. Food Saf. 2020, 19, 574–594.
  42. Awad, A.M.; Bradley, M.C.; Fernández-Del-Río, L.; Nag, A.; Tsui, H.S.; Clarke, C.F. Coenzyme Q10 deficiencies: Pathways in yeast and humans. Essays Biochem. 2018, 62, 361–376.
  43. Quinzii, C.M.; López, L.C.; Gilkerson, R.W.; Dorado, B.; Coku, J.; Naini, A.B.; Lagier-Tourenne, C.; Schuelke, M.; Salviati, L.; Carrozzo, R.; et al. Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. FASEB J. 2010, 24, 3733–3743.
  44. Quinzii, C.M.; Luna-Sanchez, M.; Ziosi, M.; Hidalgo-Gutierrez, A.; Kleiner, G.; Lopez, L.C. The role of sulfide oxidation impairment in the pathogenesis of primary CoQ deficiency. Front. Physiol. 2017, 8, 525.
  45. Heaton, R.A.; Heales, S.; Rahman, K.; Sexton, D.W.; Hargreaves, I. The Effect of Cellular Coenzyme Q10 Deficiency on Lysosomal Acidification. J. Clin. Med. 2020, 9, 1923.
  46. Rötig, A.; Appelkvist, E.L.; Geromel, V.; Chretien, D.; Kadhom, N.; Edery, P.; Lebideau, M.; Dallner, G.; Munnich, A.; Ernster, L.; et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000, 356, 391–395.
  47. Mollet, J.; Giurgea, I.; Schlemmer, D.; Dallner, G.; Chretien, D.; Delahodde, A.; Bacq, D.; de Lonlay, P.; Munnich, A.; Rötig, A. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J. Clin. Investig. 2007, 117, 765–772.
  48. Qu, J.; Kaufman, Y.; Washington, I. Coenzyme Q10 in the human retina. Investig. Ophthalmol. Vis. Sci. 2009, 50, 1814–1818.
  49. Dusting, G.J.; Triggle, C. Are we over oxidized? Oxidative stress, cardiovascular disease, and the future of intervention studies with antioxidants. Vasc. Health Risk Manag. 2005, 1, 93–97.
  50. Nunomura, A.; Moreira, P.I.; Lee, H.G.; Zhu, X.; Castellani, R.J.; Smith, M.A.; Perry, G. Neuronal Death and Survival Under Oxidative Stress in Alzheimer and Parkinson Diseases. CNS Neurol. Disord. Drug Targets 2008, 6, 411–423.
  51. Lenaz, G. Role of mitochondria in oxidative stress and ageing. Biochim. Biophys. Acta Bioenerg. 1998, 1366, 53–67.
  52. Sas, K.; Szabó, E.; Vécsei, L. Mitochondria, Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection. Molecules 2018, 23, 191.
  53. Bilbao-Malavé, V.; González-Zamora, J.; de la Puente, M.; Recalde, S.; Fernandez-Robredo, P.; Hernandez, M.; Layana, A.G.; Saenz de Viteri, M. Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Age Related Macular Degeneration, Role in Pathophysiology, and Possible New Therapeutic Strategies. Antioxidants 2021, 10, 1170.
  54. Schniertshauer, D.; Gebhard, D.; Bergemann, J. Age-Dependent Loss of Mitochondrial Function in Epithelial Tissue Can Be Reversed by Coenzyme Q10. J Aging Res. 2018, 2018, 6354680.
  55. Lee, D.; Shim, M.S.; Kim, K.Y.; Noh, Y.H.; Kim, H.; Kim, S.Y.; Weinreb, R.N.; Ju, W.K. Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress–mediated mitochondrial alteration in a mouse model of glaucoma. Investig. Ophthalmol. Vis. Sci. 2014, 55, 993–1005.
  56. Miles, M.V. The uptake and distribution of coenzyme Q10. Mitochondrion 2007, 7, S72–S77.
  57. Nucci, C.; Tartaglione, R.; Cerulli, A.; Mancino, R.; Spano, A.; Cavaliere, F.; Rombola, L.; Bagetta, G.; Corasaniti, M.T.; Morrone, L.A. Retinal damage caused by high intraocular pressure–induced transient ischemia is prevented by coenzyme Q10 in rat. Int. Rev. Neurobiol. 2007, 82, 397–406.
  58. Russo, R.; Cavaliere, F.; Rombolà, L.; Gliozzi, M.; Cerulli, A.; Nucci, C.; Fazzi, E.; Bagetta, G.; Corasaniti, M.T.; Morrone, L.A. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection. Prog. Brain Res. 2008, 173, 575–582.
  59. Mancini, A.; Festa, R.; Raimondo, S.; Pontecorvi, A.; Littarru, G.P. Hormonal influence on coenzyme Q10 levels in blood plasma. Int. J. Mol. Sci. 2011, 12, 9216–9225.
  60. Shishodia, S. Molecular mechanisms of curcumin action: Gene expression. Biofactors 2013, 39, 37–55.
  61. Mordi, R.C.; Ademosun, O.T.; Ajanaku, C.O.; Olanrewaju, I.O.; Walton, J.C. Free Radical Mediated Oxidative Degradation of Carotenes and Xanthophylls. Molecules 2020, 25, 1038.
  62. Moukarzel, A.A.; Bejjani, R.A.; Fares, F.N. Xanthophylls and eye health of infants and adults. J. Med. Liban. 2009, 57, 261–267.
  63. Yuan, J.P.; Peng, J.; Yin, K.; Wang, J.H. Potential health-promoting effects of astaxanthin: A high-value carotenoid mostly from microalgae. Mol. Nutr. Food Res. 2011, 55, 150–165.
  64. Kidd, P. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Altern. Med. Rev. 2011, 16, 355–364.
  65. Fakhri, S.; Abbaszadeh, F.; Dargahi, L.; Jorjani, M. Astaxanthin: A mechanistic review on its biological activities and health benefits. Pharmacol. Res. 2018, 136, 1–20.
  66. Ambati, R.R.; Phang, S.M.; Ravi, S.; Aswathanarayana, R.G. Astaxanthin: Sources, extraction, stability, biological activities and its commercial applications—A review. Mar. Drugs 2014, 12, 128–152.
  67. Davinelli, S.; Nielsen, M.E.; Scapagnini, G. Astaxanthin in Skin Health, Repair, and Disease: A Comprehensive Review. Nutrients 2018, 10, 522.
  68. Giannaccare, G.; Pellegrini, M.; Senni, C.; Bernabei, F.; Scorcia, V.; Cicero, A.F.G. Clinical Applications of Astaxanthin in the Treatment of Ocular Diseases: Emerging Insights. Mar. Drugs 2020, 18, 239.
  69. Nishida, Y.; Nawaz, A.; Hecht, K.; Tobe, K. Astaxanthin as a Novel Mitochondrial Regulator: A New Aspect of Carotenoids, beyond Antioxidants. Nutrients 2021, 14, 107.
  70. Higuera-Ciapara, I.; Félix-Valenzuela, L.; Goycoolea, F.M. Astaxanthin: A review of its chemistry and applications. Crit. Rev. Food Sci. Nutr. 2006, 46, 185–196.
  71. McNulty, H.P.; Byun, J.; Lockwood, S.F.; Jacob, R.F.; Mason, R.P. Differential effects of carotenoids on lipid peroxidation due to membrane interactions: X-ray diffraction analysis. Biochim. Biophys. Acta 2007, 1768, 167–174.
  72. Choi, H.D.; Kim, J.H.; Chang, M.J.; Kyu-Youn, Y.; Shin, W.G. Effects of astaxanthin on oxidative stress in overweight and obese adults. Phytother. Res. 2011, 25, 1813–1818.
  73. Grattagliano, I.; Palmieri, V.O.; Portincasa, P.; Moschetta, A.; Palasciano, G. Oxidative stress-induced risk factors associated with the metabolic syndrome: A unifying hypothesis. J. Nutr. Biochem. 2008, 19, 491–504.
  74. Kim, J.H.; Chang, M.J.; Choi, H.D. Protective effects of Haematococcus astaxanthin on oxidative stress in healthy smokers. J. Med. Food 2011, 14, 1469–1475.
  75. Xue, X.L.; Han, X.D.; Li, Y.; Chu, X.F.; Miao, W.M.; Zhang, J.L.; Fan, S.J. Astaxanthin attenuates total body irradiation-induced hematopoietic system injury in mice via inhibition of oxidative stress and apoptosis. Stem Cell Res. Ther. 2017, 8, 7.
  76. Fang, Q.; Guo, S.; Zhou, H.; Han, R.; Wu, P.; Han, C. Astaxanthin protects against early burn-wound progression in rats by attenuating oxidative stress-induced inflammation and mitochondria-related apoptosis. Sci. Rep. 2017, 7, 41440.
  77. Macedo, R.C.; Bolin, A.P.; Marin, D.P.; Otton, R. Astaxanthin addition improves human neutrophils function: In vitro study. Eur. J. Nutr. 2010, 49, 447–457.
  78. De la Fuente, M. Effects of antioxidants on immune system ageing. Eur. J. Clin. Nutr. 2002, 56, S5–S8.
  79. Yamagishi, R.; Aihara, M. Neuroprotective effect of astaxanthin against rat retinal ganglion cell death under various stresses that induce apoptosis and necrosis. Mol. Vis. 2014, 20, 1796–1805.
  80. Otsuka, T.; Shimazawa, M.; Nakanishi, T.; Ohno, Y.; Inoue, Y.; Tsuruma, K.; Ishibashi, T.; Hara, H. Protective effects of a dietary carotenoid, astaxanthin, against light-induced retinal damage. J. Pharmacol. Sci. 2013, 123, 209–218.
  81. Libkind, D.; Moliné, M.; Colabella, F. Isolation and Selection of New Astaxanthin-Producing Strains of Phaffia rhodozyma. Methods Mol Biol. 2018, 1852, 297–310.
  82. O’Neill, M.K.; Piligian, B.F.; Olson, C.D.; Woodruff, P.J.; Swarts, B.M. Tailoring Trehalose for Biomedical and Biotechnological Applications. Pure Appl. Chem. 2017, 89, 1223–1249.
  83. Hosseinpour-Moghaddam, K.; Caraglia, M.; Sahebkar, A. Autophagy induction by trehalose: Molecular mechanisms and therapeutic impacts. J. Cell. Physiol. 2018, 233, 6524–6543.
  84. Stewart, S.; He, X. Intracellular Delivery of Trehalose for Cell Banking. Langmuir 2018, 35, 7414–7422.
  85. Zhang, M.; Oldenhof, H.; Sieme, H.; Wolkers, W.F. Combining endocytic and freezing-induced trehalose uptake for cryopreservation of mammalian cells. Biotechnol. Prog. 2017, 33, 229–235.
  86. Menzies, F.M.; Fleming, A.; Caricasole, A.; Bento, C.F.; Andrews, S.P.; Ashkenazi, A.; Füllgrabe, J.; Jackson, A.; Jimenez Sanchez, M.; Karabiyik, C.; et al. Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities. Neuron 2017, 93, 1015–1034.
  87. Takahashi, S.; Isaka, M.; Hamaishi, M.; Imai, K.; Orihashi, K.; Sueda, T. Trehalose protects against spinal cord ischemia in rabbits. J. Vasc. Surg. 2014, 60, 490–496.
  88. Portbury, S.D.; Hare, D.J.; Finkelstein, D.I.; Adlard, P.A. Trehalose improves traumatic brain injury-induced cognitive impairment. PLoS ONE 2017, 12, e0183683.
  89. Maiuolo, J.; Macrì, R.; Bava, I.; Gliozzi, M.; Musolino, V.; Nucera, S.; Carresi, C.; Scicchitano, M.; Bosco, F.; Scarano, F.; et al. Myelin Disturbances Produced by Sub-Toxic Concentration of Heavy Metals: The Role of Oligodendrocyte Dysfunction. Int. J. Mol. Sci. 2019, 20, 4554.
  90. Meyer, N.; Rinholm, J.E. Mitochondria in Myelinating Oligodendrocytes: Slow and Out of Breath. Metabolites 2021, 11, 359.
  91. Ugarte, M.; Osborne, N.N. Recent advances in the understanding of the role of zinc in ocular tissues. Metallomics 2014, 6, 189–200.
  92. Sarkar, S.; Davies, J.E.; Huang, Z.; Tunnacliffe, A.; Rubinsztein, D.C. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 2007, 282, 5641–5652.
  93. Zhang, Y.; DeBosch, B.J. Using trehalose to prevent and treat metabolic function: Effectiveness and mechanisms. Curr. Opin. Clin. Nutr. Metab. Care 2019, 22, 303–310.
  94. Kaushik, J.K.; Bhat, R. Why trehalose an exceptional protein stabilizer? An analysis of the thermal stability of proteins in the presence of the compatible osmolyte trehalose. J. Biol. Chem. 2003, 278, 26458–26465.
  95. Jain, N.K.; Roy, I. Trehalose and protein stability. Curr. Protoc. Protein Sci. 2010, 59, 4–9.
  96. Hill-Bator, A.; Misiuk-Hojto, M.; Marycz, K.; Grzesiak, J. Trehalose-based eye drops preserve viability and functionality of cultured human corneal epithelial cells during desiccation. Biomed. Res. Int. 2014, 2014, 292139.
  97. Elbein, A.D.; Pan, Y.T.; Pastuszak, I.; Carroli, D. New insights on trehalose: A multifunctional molecule. Glycobiology 2003, 13, 17R–27R.
  98. Laihia, J.; Kaarniranta, K. Trehalose for Ocular Surface Health. Biomolecules 2020, 10, 809.
  99. Lee, H.J.; Yoon, Y.S.; Lee, S.J. Mechanism of neuroprotection by trehalose: Controversy surrounding autophagy induction. Cell Death Dis. 2018, 9, 712.
  100. Chiambaretta, F.; Doan, S.; Labetoulle, M.; Rocher, N.; Fekin, L.E.; Messaoud, R.; Khairallah, M.; Baudouin, C. A randomized, controlled study of the efficacy and safety of new eyedrop formulation for moderate to severe dry eye. Eur. J. Ophthalmol. 2017, 27, 1–9.
  101. Lievens, C.; Berdy, G.; Douglass, D.; Montaquila, S.; Lin, H.; Simmons, P.; Carlisle-Wilcox, C.; Vehige, J.; Haque, S. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study. Cont Lens Anterior Eye. 2019, 42, 443–449.
  102. Pinto-Bonilla, J.C.; Del Olmo-Jimeno, A.; Llovet-Osuna, F.; Hernander-Gallilea, E. A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment:patient satisfaction in the treatment of dry eye syndrome. Ther. Clin. Risk Manag. 2015, 11, 595–603.
  103. Čejková, J.; Stipek, S.; Crkovska, J.; Ardan, T.; Platenik, J.; Cejka, C.; Midelfart, A. UV Rays, the prooxidant/antioxidant imbalance in the cornea and oxidative damage. Physiol. Res. 2004, 53, 1–10.
  104. Čejková, J.; Cejka, C.; Luyckx, J. Trehalose treatment accelerates the healing of UVB-irradiated corneas. Comparative immunohistochemical studies on corneal cryostat sections and corneal impression cytology. Histol. Histopathol. 2012, 27, 1029–1040.
  105. Talero, E.; Ávila-Roman, J.; Motilva, V. Chemoprevention with phytonutrients and microalgae products in chronic inflammation and colon cancer. Curr. Pharm Des. 2012, 18, 3939–3965.
  106. Taylor, R.A.; Leonard, M.C. Curcumin for inflammatory bowel disease: A review of human studies. Altern. Med. Rev. 2011, 16, 152–156.
  107. Carmona-Ramírez, I.; Santamaría, A.; Tobón-Velasco, J.C.; Orozco-Ibarra, M.; González-Herrera, I.G.; Pedraza-Chaverrí, J.; Maldonado, P.D. Curcumin restores Nrf2 levels and prevents quinolinic acid-induced neurotoxicity. J. Nutr. Biochem. 2013, 24, 14–24.
  108. Aggarwal, S.; Ichikawa, H.; Takada, Y.; Sandur, S.K.; Shishodia, S.; Aggarwal, B.B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα Kinase and akt activation. Mol. Pharmacol. 2006, 69, 195–206.
  109. Prudʼhomme, G.J. Cancer stem cells and novel targets for antitumor strategies. Curr. Pharm. Des. 2012, 18, 2838–2849.
  110. Radomska-Leśniewska, D.M.; Osiecka-Iwan, A.; Hyc, A.; Góźdź, A.; Dąbrowska, A.M.; Skopiński, P. Therapeutic potential of curcumin in eye diseases. Cent. Eur. J. Immunol. 2019, 44, 181–189.
  111. Menon, V.P.; Sudheer, A.R. Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol. 2007, 595, 105–125.
  112. Lin, Y.G.; Kunnumakkara, A.B.; Nair, A.; Merritt, W.M.; Han, L.Y.; Armaiz-Pena, G.N.; Kamat, A.A.; Spannuth, W.A.; Gershenson, D.M.; Lutgendorf, S.K.; et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clin. Cancer Res. 2007, 13, 3423–3430.
  113. Marchiani, A.; Rozzo, C.; Fadda, A.; Delogu, G.; Ruzza, P. Curcumin and curcumin-like molecules: From spice to drugs. Curr. Med. Chem. 2014, 21, 204–222.
  114. Ushio-Fukai, M.; Nakamura, Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008, 266, 37–52.
  115. Ushio-Fukai, M. Redox signaling in angiogenesis: Role of NADPH oxidase. Cardiovasc Res. 2006, 71, 226–235.
  116. Radomska-Leśniewska, D.M.; Skopiński, P.; Bałan, J.B.; Białoszewska, A.; Jóźwiak, J.; Rokicki, D.; Skopińska-Różewska, E.; Borecka, A.; Hevelke, A. Angiomodulatory properties of Rhodiola spp. And other natural antioxidants. Cent. Eur. J. Immunol. 2015, 40, 249–262.
  117. Radomska-Leśniewska, D.M.; Bałan, J.B.; Skopiński, P. Angiogenesis modulation by exogenous antioxidants. Cent. Eur. J. Immunol. 2017, 42, 370–376.
  118. Nebbioso, M.; Franzone, F.; Greco, A.; Gharbiya, M.; Bonofiglio, V.; Polimeni, A. Recent Advances and Disputes About Curcumin in Retinal Diseases. Clin. Ophthalmol. 2021, 15, 2553–2571.
  119. Munia, I.; Gafray, L.; Bringer, M.A.; Goldschmidt, P.; Proukhnitzky, L.; Jacquemot, N.; Cercy, C.; Ramchani Ben Otman, K.; Errera, M.H.; Ranchon-Cole, I. Cytoprotective effects of natural highly bio-available vegetable derivatives on human-derived retinal cells. Nutrients 2020, 12, 879.
  120. Niederkorn, J.Y.; Stern, M.E.; Pflugfelder, S.C.; De Paiva, C.S.; Corrales, R.M.; Gao, J.; Siemasko, K. Desiccating stress induces T cell-mediated Sjogren’s Syndrome-like lacrimal keratoconjunctivitis. J. Immunol. 2006, 176, 3950–3957.
  121. Li, D.Q.; Luo, L.; Chen, Z.; Li, D.-Q.; Kim, H.-S.; Song, X.J.; Pflugfelder, S.C. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp. Eye Res. 2006, 82, 588–596.
  122. Chung, S.H.; Choi, S.H.; Choi, J.A.; Chuck, R.S.; Joo, C.K. Curcumin suppresses ovalbumin-induced allergic conjunctivitis. Mol. Vis. 2012, 18, 1966–1972.
  123. Gupta, S.K.; Agarwal, R.; Srivastava, S.; Agarwal, P.; Agrawal, S.U.; Saxena, R.; Galpalli, N. The anti-inflammatory effects of Curcuma longa and Berberis aristata in endotoxin-induced uveitis in rabbits. Investig. Ophthalmol. Vis. Sci. 2008, 4, 4036–4040.
  124. Agarwal, R.; Gupta, S.K.; Agarwal, P.; Srivastava, S. Topically applied standardized aqueous extract of Curcuma longa Linn. suppresses endotoxin-induced uveal inflammation in rats. Indian J. Exp. Biol. 2013, 51, 797–803.
  125. Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K.; Gonzalez, F.J.; Grimaldi, P.A.; Kadowaki, T.; Lazar, M.A.; O’Rahilly, S.; et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58, 726–741.
  126. Salehi, M.; Mashhadi, N.S.; Esfahani, P.S.; Feizi, A.; Hadi, A.; Askari, G. The Effects of Curcumin Supplementation on Muscle Damage, Oxidative Stress, and Inflammatory Markers in Healthy Females with Moderate Physical Activity: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Int. J. Prev. Med. 2021, 12, 94.
  127. Xu, D.; Hu, M.J.; Wang, Y.Q.; Cui, Y.L. Antioxidant Activities of Quercetin and Its Complexes for Medicinal Application. Molecules 2019, 24, 1123.
  128. Tang, S.M.; Deng, X.T.; Zhou, J.; Li, Q.P.; Ge, X.X.; Miao, L. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomed. Pharmacother. 2020, 121, 109604.
  129. Reyes-Farias, M.; Carrasco-Pozo, C. The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism. Int. J. Mol. Sci. 2019, 20, 3177.
  130. Capriglione, F.; Maiuolo, J.; Celano, M.; Damante, G.; Russo, D.; Bulotta, S.; Maggisano, V. Quercetin Protects Human Thyroid Cells against Cadmium Toxicity. Int. J. Mol. Sci. 2021, 22, 6849.
  131. Shen, C.Y.; Jiang, J.G.; Yan, G.L.; Wang, D.W.; Zhu, W. Anti-ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine: Pharmacological mechanisms and implications for drug discovery. Br. J. Pharmacol. 2017, 174, 1395–1425.
  132. Shen, P.; Lin, W.; Deng, X.; Ba, X.; Han, L.; Chen, Z.; Qin, K.; Huang, Y.; Tu, S. Potential Implications of Quercetin in Autoimmune Diseases. Front. Immunol. 2021, 12, 689044.
  133. Yi, H.; Peng, H.; Wu, X.; Xu, X.; Kuang, T.; Zhang, J.; Fan, G. The Therapeutic Effects and Mechanisms of Quercetin on Metabolic Diseases: Pharmacological Data and Clinical Evidence. Oxid. Med. Cell Longev. 2021, 2021, 6678662.
  134. McKay, T.B.; Karamichos, D. Quercetin and the ocular surface: What we know and where we are going. Exp. Biol. Med. 2017, 242, 565–572.
  135. Liu, Y.; Gan, L.; Carlsson, D.J.; Fagerholm, P.; Lagali, N.; Watsky, M.A.; Munger, R.; Hodge, W.G.; Priest, D.; Griffith, M. A simple, cross-linked collagen tissue substitute for corneal implantation. Investig. Ophthalmol. Vis. Sci. 2006, 47, 1869–1875.
  136. Davies, N.M. Biopharmaceutical considerations in topical ocular drug delivery. Clin. Exp. Pharmacol. Physiol. 2000, 27, 558–562.
  137. Nishimuro, H.; Ohnishi, H.; Sato, M.; Ohnishi-Kameyama, M.; Matsunaga, I.; Naito, S.; Ippoushi, K.; Akasaka, H.; Saitoh, S.; Shimamoto, K.; et al. Estimated daily intake and seasonal food sources of quercetin in Japan. Nutrients 2015, 7, 2345–2358.
  138. Neamtu, A.A.; Maghiar, T.A.; Alaya, A.; Olah, N.K.; Turcus, V.; Neamtu, C.; Maghiar, A.M.; Mathe, E. A Comprehensive View on the Quercetin Impact on Colorectal Cancer. Molecules 2022, 27, 1873.
  139. Oppedisano, F.; Bulotta, R.M.; Maiuolo, J.; Gliozzi, M.; Musolino, V.; Carresi, C.; Ilari, S.; Serra, M.; Muscoli, C.; Gratteri, S.; et al. The Role of Nutraceuticals in Osteoarthritis Prevention and Treatment: Focus on n-3 PUFAs. Oxid. Med. Cell Longev. 2021, 2021, 4878562.
  140. Mollace, V.; Gliozzi, M.; Carresi, C.; Musolino, V.; Oppedisano, F. Re-assessing the mechanism of action of n-3 PUFAs. Int. J. Cardiol. 2013, 170 (Suppl. 1), S8–S11.
  141. Oppedisano, F.; Macrì, R.; Gliozzi, M.; Musolino, V.; Carresi, C.; Maiuolo, J.; Bosco, F.; Nucera, S.; Zito, M.C.; Guarnieri, L.; et al. The Anti-Inflammatory and Antioxidant Properties of n-3 PUFAs: Their Role in Cardiovascular Protection. Biomedicines 2020, 8, 306.
  142. Oppedisano, F.; Mollace, R.; Tavernese, A.; Gliozzi, M.; Musolino, V.; Macrì, R.; Carresi, C.; Maiuolo, J.; Serra, M.; Cardamone, A.; et al. PUFA Supplementation and Heart Failure: Effects on Fibrosis and Cardiac Remodeling. Nutrients 2021, 13, 2965.
  143. Oppedisano, F.; Maiuolo, J.; Gliozzi, M.; Musolino, V.; Carresi, C.; Nucera, S.; Scicchitano, M.; Scarano, F.; Bosco, F.; Macrì, R.; et al. The Potential for Natural Antioxidant Supplementation in the Early Stages of Neurodegenerative Disorders. Int. J. Mol. Sci. 2020, 21, 2618.
  144. Gong, Y.; Fu, Z.; Liegl, R.; Chen, J.; Hellström, A.; Smith, L.E. ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases. Am. J. Clin. Nutr. 2017, 106, 16–26.
  145. Kalogerou, M.; Kolovos, P.; Prokopiou, E.; Papagregoriou, G.; Deltas, C.; Malas, S.; Georgiou, T. Omega-3 fatty acids protect retinal neurons in the DBA/2J hereditary glaucoma mouse model. Exp. Eye Res. 2018, 167, 128–139.
  146. Bao, J.; Yang, Z.; Zheng, S.; Li, J.; Shentu, X. Circulating fatty acids and risk of primary open-angle glaucoma: A mendelian randomization study. Gene 2022, 811, 146078.
  147. Romeo Villadóniga, S.; Rodríguez García, E.; Sagastagoia Epelde, O.; Álvarez Díaz, M.D.; Domingo Pedrol, J.C. Effects of Oral Supplementation with Docosahexaenoic Acid (DHA) plus Antioxidants in Pseudoexfoliative Glaucoma: A 6-Month Open-Label Randomized Trial. J. Ophthalmol. 2018, 2018, 8259371.
  148. Da Costa Morato Nery, D.; da Silva, C.G.; Mariani, D.; Fernandes, P.N.; Pereira, M.D.; Panek, A.D.; Eleutherio, E.C. The role of trehalose and its transporter in protection against reactive oxygen species. Biochim. Biophys. Acta 2008, 1780, 1408–1411.
  149. Saccà, S.C.; Cutolo, C.A.; Ferrari, D.; Corazza, P.; Traverso, C.E. The Eye, Oxidative Damage and Polyunsaturated Fatty Acids. Nutrients 2018, 10, 668.
  150. Padmanabha, S.; Vallikannan, B. Fatty acids modulate the efficacy of lutein in cataract prevention: Assessment of oxidative and inflammatory parameters in rats. Biochem. Biophys. Res. Commun. 2018, 500, 435–442.
  151. Padmanabha, S.; Vallikannan, B. Fatty acids influence the efficacy of lutein in the modulation of α-crystallin chaperone function: Evidence from selenite induced cataract rat model. Biochem. Biophys. Res. Commun. 2020, 529, 425–431.
  152. Monagas, M.; Quintanilla-López, J.E.; Gómez-Cordovés, C.; Bartolomé, B.; Lebrón-Aguilar, R. MALDI-TOF MS analysis of plant proanthocyanidins. J. Pharm Biomed. Anal. 2010, 51, 358–372.
  153. Prasain, J.K.; Peng, N.; Dai, Y.; Moore, R.; Arabshahi, A.; Wilson, L. Liquid chromatography tandem mass spectrometry identification of proanthocyanidins in rat plasma after oral administration of grape seed extract. Phytomedicine 2009, 16, 233–243.
  154. Gao, Z.; Liu, G.; Hu, Z.; Shi, W.; Chen, B.; Zou, P. Grape seed proanthocyanidins protect against streptozotocin-induced diabetic nephropathy by attenuating endoplasmic reticulum stress-induced apoptosis. Mol. Med. Rep. 2018, 18, 1447–1454.
  155. Décordé, K.; Teissèdre, P.L.; Sutra, T.; Ventura, E.; Cristol, J.P.; Rouanet, J.M. Chardonnay grape seed procyanidin extract supplementation prevents high-fat diet-induced obesity in hamsters by improving adipokine imbalance and oxidative stress markers. Mol. Nutr. Food Res. 2009, 53, 659–666.
  156. Chacón, M.R.; Ceperuelo-Mallafré, V.; Maymó-Masip, E.; Mateo-Sanz, J.M.; Arola, L.; Guitiérrez, C. Grape-seed procyanidins modulate inflammation on human differentiated adipocytes in vitro. Cytokine 2009, 47, 137–142.
  157. Hao, J.P.; Shi, H.; Zhang, J.; Zhang, C.M.; Feng, Y.M.; Qie, L.Y. Role of GSPE in improving early cerebral vascular damage by inhibition of Profilin-1 expression in a ouabain-induced hypertension model. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 6999–7012.
  158. Xianchu, L.; Ming, L.; Xiangbin, L.; Lan, Z. Grape seed proanthocyanidin extract supplementation affects exhaustive exercise-induced fatigue in mice. Food Nutr. Res. 2018, 62, 62.
  159. Yang, D.; Li, S.; Gao, L.; Lv, Z.; Bing, Q.; Lv, Q. Dietary grape seed procyanidin extract protects against leadinduced heart injury in rats involving endoplasmic reticulum stress inhibition and AKT activation. J. Nutr. Biochem. 2018, 62, 43–49.
  160. Pons, Z.; Margalef, M.; Bravo, F.I.; Arola-Arnal, A.; Muguerza, B. Chronic administration of grape-seed polyphenols attenuates the development of hypertension and improves other cardiometabolic risk factors associated with the metabolic syndrome in cafeteria diet-fed rats. Br. J. Nutr. 2017, 117, 200–208.
  161. Pinent, M.; Bladé, C.; Salvadó, M.J.; Blay, M.; Pujadas, G.; Fernández-Larrea, J. Procyanidin effects on adipocyterelated pathologies. Crit. Rev. Food Sci. Nutr. 2006, 46, 543–550.
  162. Jhun, J.Y.; Moon, S.J.; Yoon, B.Y.; Byun, J.K.; Kim, E.K.; Yang, E.J. Grape seed proanthocyanidin extract-mediated regulation of STAT3 proteins contributes to Treg differentiation and attenuates inflammation in a murine model of obesity-associated arthritis. PLoS ONE 2013, 8, e78843.
  163. Sherif, A.A.; Abdelhalim, S.Z.; Salim, E.I. Immunohistochemical and biochemical alterations following administration of proanthocyanidin extract in rats hepatocellular carcinoma. Biomed. Pharmacother. 2017, 93, 1310–1319.
  164. Bagchi, D.; Bagchi, M.; Stohs, S.J.; Das, D.K.; Ray, S.D.; Kuszynski, C.A. Free radicals and grape seed proanthocyanidin extract: Importance in human health and disease prevention. Toxicology 2000, 148, 187–197.
  165. Mollace, V.; Rosano, G.M.C.; Anker, S.D.; Coats, A.J.S.; Seferovic, P.; Mollace, R.; Tavernese, A.; Gliozzi, M.; Musolino, V.; Carresi, C.; et al. Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review. Nutrients 2021, 13, 257.
  166. Rodríguez-Pérez, C.; García-Villanova, B.; Guerra-Hernández, E.; Verardo, V. Grape Seeds proanthocyanidins: An overview of in vivo bioactivity in animal models. Nutrients 2019, 11, 2435.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback